Replies to post #98949 on Cytodyn Inc (CYDY)

[Blue Man]

Related to what? Our CEO is with Cytodyn/Leronlimab. This is a different mAb. I was texting a critical care doc with the teaching hospital here. He is followed by doctors here, nurses, and the community. He gives updates on his patients at two hospitals who are critical and on vents. He is following SOC (Remdesivir + steriod). He is not having great success and said he is waiting for a mAb to be approved and is watching the trials. He said he would "love" to use an mAb and will as soon as one is approved. He is having trouble with the immune suppression caused by the disease and the steroid. He did not specifically mention leronlimab or his awareness of it (though I asked if he was aware). I do not think he is alone in his thought. He knows SOC is not working. He knows steriods are causing issues related to the immune system. Shoot, every doctor and nurse knows this side effect to steriods.

[Scooter McCabe]

So Humanigen is in phase 3. It's in your own article you posted earlier today. We are in phase 2. If the FDA is looking at phase 3 trials, they won't be looking at us.

If our phase 2 trials are good, we could get emergency approval while Humanigen is in a competition trial.

That competition trial might also be an issue for them because to compare it they may have to drop some of the exclusion criteria that has protected them thus far.

The plus side for them is Remdesivir set a very low bar, same low bar we will get to enjoy.

Humanigen still has it's safety data to deal with and I don't seem to recall them publishing any of that data or its been rather low key.